Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

39 / 39

Conclusions
• 2nd G ALK TKI remains the SoC for majority.
• Strategies at PD is an issue.
• Crizotinib activity into the brain specially
with local therapies.
• Personalised treatment upfront a challenge?.
• Access to new strategies can be an issue.